Evinacumab (Evkeeza): how it works, status and trials
Approved 2021 (HoFH)Injected proteinLowering triglycerides
Evinacumab (Evkeeza) is an infusion that neutralizes ANGPTL3, a protein that slows the breakdown of fats in the blood. It lowers LDL without needing working LDL receptors, and it is approved for homozygous familial hypercholesterolemia (HoFH).
In technical terms: Neutralises ANGPTL3, releasing the brake on lipoprotein and endothelial lipase. Lowers LDL-C without needing LDL receptors.
The highlighted badge marks where Evinacumab (Evkeeza) acts. Open the full map or compare every therapy.
At a glance
- Acts on
- ANGPTL3 protein · blood
- How it is given
- Monoclonal antibody · IV every 4 weeks
- What the main trial found
- LDL-C −49 pp in HoFH (ELIPSE); TG ↓
- Status (curated October 25, 2026)
- Approved 2021 (HoFH)
Where it fits in the body
Triglyceride-rich lipoproteins
VLDL from the liver and chylomicrons from the gut carry triglyceride. Lipoprotein lipase (LPL) on capillary walls breaks it down. ANGPTL3 and apoC-III act as brakes on this process. Removing either brake (11–15) lowers triglycerides, and ANGPTL3 blockade also lowers LDL-C without needing LDL receptors, which matters in homozygous FH.
Trials and registry status
From ClinicalTrials.gov, PubMed and openFDA, refreshed monthly. Last run October 27, 2026.
Evinacumab (Evkeeza) from Regeneron
Stage: US approved 2021-02-11. 1 active of 12 registered trials. 4 new papers in the last 31 days.
- NCT03409744 (NCT03409744): completed, primary completion 2023-04-13, results posted
Recent changes
- October 25, 2026: PMID 42828246: Clinical considerations on the use of evinacumab for the treatment of homozygous familial hypercholesterolemia.
Evidence
- ELIPSE HoFH (PubMed 32813947)
Common questions
How does Evinacumab (Evkeeza) work?
Evinacumab (Evkeeza) is an infusion that neutralizes ANGPTL3, a protein that slows the breakdown of fats in the blood. It lowers LDL without needing working LDL receptors, and it is approved for homozygous familial hypercholesterolemia (HoFH). In technical terms: Neutralises ANGPTL3, releasing the brake on lipoprotein and endothelial lipase. Lowers LDL-C without needing LDL receptors. It acts on ANGPTL3 protein · blood.
How much does Evinacumab (Evkeeza) lower cholesterol or other lipids?
LDL-C −49 pp in HoFH (ELIPSE); TG ↓. Individual results differ, and a clinician can say what to expect for one person.
Is Evinacumab (Evkeeza) approved, and what is the status?
Approved 2021 (HoFH) (curated October 25, 2026). Registry stage as of October 27, 2026: Evinacumab, US approved 2021-02-11.
How is Evinacumab (Evkeeza) taken?
Monoclonal antibody · IV every 4 weeks.
Read more
Related therapies
- Olezarsen (Tryngolza) and volanesorsen: Olezarsen approved 2024; volanesorsen EU only
- Plozasiran (Redemplo): Approved Nov 2025 (FCS)
- Fibrates (fenofibrate): Approved (generic)
- Icosapent ethyl (Vascepa): Approved
Educational, not medical advice. Mechanism and status text curated October 25, 2026; registry data refreshed October 27, 2026. Registries can lag company announcements. Effects are placebo-adjusted results from the main published trial, not head-to-head comparisons. Investigational agents are available only in clinical trials. Preval Health does not practice medicine; licensed clinicians in a partner network provide care. If you have chest pain or signs of a stroke, call 911.